Skip to main content

A Double Blind, Randomized, Placebo-controlled, Single Center, Phase 2a Study to Determine the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ISIS 463588 Administered Subcutaneously Once Weekly for 13 Weeks in Obese Patients

A Double Blind, Randomized, Placebo-controlled, Single Center, Phase 2a Study to Determine the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ISIS 463588 Administered Subcutaneously Once Weekly for 13 Weeks in Obese Patients

Principal Investigator

Sponsor

Isis Pharmaceuticals

The purpose of this research study is to find out more about the safety and tolerability of an investigational drug called ISIS 463588. This experimental drug is not approved by any regulatory health agency. ISIS 463588 is given by subcutaneous injection. A subcutaneous injection is an injection given into the tissue just below the skin.